Literature DB >> 11986240

Cytomorphologic, immunohistochemical, and cytogenetic profiles of follicular lymphoma: 2 types of follicular lymphoma grade 3.

German Ott1, Tiemo Katzenberger, Andreas Lohr, Steffi Kindelberger, Thomas Rüdiger, Martin Wilhelm, Jörg Kalla, Andreas Rosenwald, Justus G Müller, M Michaela Ott, Hans Konrad Müller-Hermelink.   

Abstract

Follicular lymphoma (FL) grades 1 and 2 are regarded as a distinct disease entity, whereas data suggest that FL grade 3 might be an inhomogeneous tumor category. To define the biologic spectrum of FL, 89 follicular lymphomas were studied for their cytologic composition, antigen expression, mitotic and proliferation indices, cytogenetics, and clinical data. In contrast to the homogeneous appearance of FL grades 1 and 2 (29 and 33 cases, respectively), 2 types of FL grade 3 were recognized. Eleven cases of FL 3a displayed structural features similar to those of FL 1 and 2 and were composed of centroblasts and centrocytes, whereas 16 cases of FL 3b, with (n = 4) or without (n = 12) a diffuse large B-cell lymphoma component (DLBL) (FL 3b +/- DLBL), consisted exclusively of blasts. In contrast to FL 3a, FL 3b +/- DLBL were CD10(+) in only 50% of cases and displayed plasmacytoid differentiation in 44% of cases. Although FL3a was t(14;18)+ in 8 of 11 (73%) cases, only 2 of 16 (13%) FL3b +/- DLBLs harbored this translocation. In contrast, chromosomal breaks at 3q27 were encountered in 7 of 16 (44%) FL 3b +/- DLBL in contrast to only 2 of 11 (18%) FL 3a, and the spectrum of secondary aberrations in FL 3b +/- DLBL was similar to that of diffuse large B-cell lymphoma. We conclude, therefore, that FL grade 3 is a heterogeneous disease group and that the distinction proposed in the new World Health Organization classification between FL 3a (with centrocytes) and FL3b (without centrocytes) is of biologic, and possibly clinical, importance.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11986240     DOI: 10.1182/blood.v99.10.3806

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  44 in total

1.  Cytogenetic alterations affecting BCL6 are predominantly found in follicular lymphomas grade 3B with a diffuse large B-cell component.

Authors:  Tiemo Katzenberger; German Ott; Thomas Klein; Jörg Kalla; Hans Konrad Müller-Hermelink; M Michaela Ott
Journal:  Am J Pathol       Date:  2004-08       Impact factor: 4.307

2.  Bendamustine plus Rituximab Versus R-CHOP as First-Line Treatment for Patients with Follicular Lymphoma Grade 3A: Evidence from a Multicenter, Retrospective Study.

Authors:  Patrizia Mondello; Normann Steiner; Wolfgang Willenbacher; Claudio Cerchione; Davide Nappi; Endri Mauro; Simone Ferrero; Salvatore Cuzzocrea; Michael Mian
Journal:  Oncologist       Date:  2018-01-09

3.  Methotrexate-associated lymphoproliferative disorder mimicking composite lymphoma.

Authors:  Jun-ichiro Ikeda; Eiichi Morii; Yasuhiko Tomita; Jing-Xian Xu; Hayato Kimura; Masaharu Kohara; Yoshihiko Hoshida; Katsuyuki Aozasa
Journal:  Int J Hematol       Date:  2006-05       Impact factor: 2.490

4.  A case of an abdominal mass: follicular lymphoma.

Authors:  Tina L Walker; Gabriel E Lopez
Journal:  Perm J       Date:  2011

5.  Demonstration of array-based analysis for highly multiplexed PCR assays application to detection of IGH@-BCL2 translocations in FFPE follicular lymphoma specimens.

Authors:  Janice M Spence; Paul G Rothberg; Nancy Wang; W Richard Burack
Journal:  J Mol Diagn       Date:  2011-05       Impact factor: 5.568

Review 6.  Nodal aggressive B-cell lymphomas: a diagnostic approach.

Authors:  Sonam Prakash; Steven H Swerdlow
Journal:  J Clin Pathol       Date:  2007-03-16       Impact factor: 3.411

7.  Prognostic significance of B-cell differentiation genes encoding proteins in diffuse large B-cell lymphoma and follicular lymphoma grade 3.

Authors:  Ana Borovecki; Petra Korać; Marin Nola; Davor Ivanković; Branimir Jaksić; Mara Dominis
Journal:  Croat Med J       Date:  2008-10       Impact factor: 1.351

Review 8.  Recommendations for Clinical Trial Development in Follicular Lymphoma.

Authors:  Kami Maddocks; Paul M Barr; Bruce D Cheson; Richard F Little; Lawrence Baizer; Brad S Kahl; John P Leonard; Nathan Fowler; Leo I Gordon; Brian K Link; Jonathan W Friedberg; Stephen M Ansell
Journal:  J Natl Cancer Inst       Date:  2016-12-31       Impact factor: 13.506

Review 9.  Nodal follicular lymphoma: the role of radiotherapy for stages I and II.

Authors:  Frank Heinzelmann; Marianne Engelhard; Hellmut Ottinger; Michael Bamberg; Martin Weinmann
Journal:  Strahlenther Onkol       Date:  2010-03-26       Impact factor: 3.621

10.  Follicular lymphoma t(14;18)-negative is genetically a heterogeneous disease.

Authors:  Dominik Nann; Joan Enric Ramis-Zaldivar; Inga Müller; Blanca Gonzalez-Farre; Janine Schmidt; Caoimhe Egan; Julia Salmeron-Villalobos; Guillem Clot; Sven Mattern; Franziska Otto; Barbara Mankel; Dolors Colomer; Olga Balagué; Vanessa Szablewski; Carmen Lome-Maldonado; Lorenzo Leoncini; Stefan Dojcinov; Andreas Chott; Christiane Copie-Bergman; Irina Bonzheim; Falko Fend; Elaine S Jaffe; Elias Campo; Itziar Salaverria; Leticia Quintanilla-Martinez
Journal:  Blood Adv       Date:  2020-11-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.